Maintenance of bone mineral density of femoral cortex in ovariectomized rats after withdrawal of concurrent administration of human parathyroid hormone (1-34) and incadronate disodium (YM175)

Journal of Bone and Mineral Metabolism

Volumn 15, Issue 4, 1997, Pages 206-212

  Zhang, Liu ^a   Takahashi, Hideaki E ^a   Tanizawa, Tatsuhiko ^a   Endo, Naoto ^a   Yamamoto, Noriaki ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Bone mineral density (BMD); Concurrent therapy; Incadronate disodium (YM175); Parathyroid hormone (PTH); Withdrawal

Indexed keywords

EID: 0344715288     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02491382     Document Type: Article

References (36)

1. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OLM, Coupron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 280:1340-1344
2. Slovik DM, Rosenthal DI, Doppelt SH, Potts JT, Daly MA, Cambell JA, Neer RM (1986) Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1:377-381
3. Gunness-Hey M, Hock JM (1989) Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone 10:447-452
4. Valkema R, Vismans F-J, Papapoulos SE, Pauwels EKJ, Bijvoet OLM (1989) Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 5:183-192
5. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271
6. Fujimoto R, Nii A, Okazaki A, Miki H, Kawashima H (1990) Effect of disodium dihydrogen (cycloheptylamino) methylene bisphosphonate monohydrate (YM175) on the bone formation and resorption in rats and dogs. Histological examination. J Bone Miner Res 5[suppl 2]: 157
7. Nagao Y, Ishitobi Y, Fukushima S, Kinoshita H, Kawashima H, Kumagawa M (1990) YM175 inhibits osteoclast differentiation and bone resorbing action of mature osteoclasts. J Bone Miner Res 5[suppl 2]: 159
8. Motoie H, Nakamura T, O'uchi N, Nishikawa H, Kanoh H, Abe T, Kawashima H (1995) Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res 10:910-920
9. Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi HE (1996) Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats. J Bone Miner Res 11: 169-177
10. Lauritzen DB, Balena R, Shea M, Seedor JG, Markatos A, Le HM, Toolan BC, Myers ER, Rodan GA, Hayes WC (1993) Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res 8:871-879
11. Wronski TJ, Yen CF, Qi H, Dann LM (1993) Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132:823-831
12. Lin BY, Jee WSS, Ma FY, Ke HZ, Kimmel DB, Li XJ (1994) Effects of prostaglandin E, and risedronate administration on cancellous bone in older female rats. Bone 15:489-496
13. Mosekilde L, Danielsen CC, Gasser J (1994) The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone (1-34), and combination therapy, assessed in aged ovariectomized rats. Endocrinology 134:2126-2134
14. Mashiba T, Tanizawa T, Takano Y, Takahashi HE, Mori S, Norimatsu H (1995) A histomorphometric study on effects of single and concurrent intermittent administration of human PTH(1-34) and bisphosponate cimadronate on tibial metaphysis in ovariectomized rats. Bone 17:5273-5278
15. 2 and risedronate administration is maintained after their withdrawal in older female rats. J Bone Miner Res 10:963-970
16. Ammann P, Rizzoli R, Slosman D, Bonjour JP (1992) Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy X-ray absorptiometry. J Bone Miner Res 7:311-316
17. Kimmel DB, Wronski TJ (1990) Nondestructive measurement of bone mineral in femurs from ovariectomized rats. Calcif Tissue Int 46:101-110
18. Wronski TJ, Walsh CC, Ignaszewski LA (1986) Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone 7:119-123
19. Wronski TJ, Cintron M, Dann LM (1988) Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int 43:179-183
20. Wronski TJ, Dann LM. Scott KS, Cintron M (1989) Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45:360-366
21. Danielsen CC, Mosekilde L, Svenstrup B (1993) Cortical bone mass, composition, and mechanical properties in female rats in regulation to age, long-term ovariectomy. and estrogen substitution. Calcif Tissue Int 52:26-33
22. 2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone 11:253-266
23. Frost HM, Jee WSS (1992) On the rat model of human osteopenias and osteoporosis. Bone Miner 18:227-281
24. Wronski TJ, Yen CF (1994) Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15:51-58
25. Yamamoto N, Takahashi HE, Tanizawa T, Fujimoto R, Hara T, Tanaka S (1993) Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH (1-34) administration. Bone Miner 23:333-342
26. Jee WSS, Tang LY, Ke HZ, Setterberg RB, Kimmel DB (1993) Maintaining restored bone with bisphosphonate in the ovariectomized rat skeleton: dynamic histomorphometry of changes in bone mass. Bone 14:493-498
27. Seedor JG, Quartuccio HA, Thompson DD (1991) The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 6:339-346
28. Wronski TJ, Dann LG, Qi H, Yen CF (1993) Skeletal effects of withdrawal of estrogen and disphosphonate treatment in ovariectomized rats. Calcif Tissue Int 53:210-216
29. Wronski TJ, Yen CF, Scott KS (1991) Estrogen and disphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res 6:387-394
30. Hesp R, Hulme P, Williams D, Reeve J (1981) The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1-34). Metab Bone Dis Relat Res 2:331-334
31. Pariesan M, Silverberg SJ, Shane E, Cruz LDL, Lindsay R, Bilezikian JP, Dempster DW (1990) The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure J Clin Endocrinol Metab 70:930-938
32. Hesch RD, Prokop M, Busch U, Delling G, Rittinghaus EF (1990) Dramatic increase of bone mass and turnover in osteoporosis by combined 1-38 hPTH and calcitonin therapy In: Takahashi HE (ed) Bone morphometry. Nishimura, Niigata, p 598
33. 3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 11:600-613
34. Fleisch H (1987) Bisphosphonates - history and experimental basis. Bone 8[suppl]:523-528
35. Schenk R, Eggli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349
36. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nillssen MHL (1995) The anabolic effect of human PTH (1-34) or bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610